Adrian Rubstein

Changing BioBusiness 1% at a time | Life Science Investment Advisor | Content Creator

[Adrian Rubstein @adrianrubstein]

@ridark_eth Eg

[Adrian Rubstein @adrianrubstein]

Are you aware of the marriage between Molecular Biology and Physics??

Let me introduce you to the Biomolexular condensates.

Want to learn more? Read the latest issue of #biobusiness

https://t.co/zk20z9x8yG

[Adrian Rubstein @adrianrubstein]

If you are a fan of the intersection of science and technology, you'll enjoy the latest edition of the #BioBusiness newsletter summary video.👇🏼👇🏼

https://t.co/hctea14ykK

#biotech #investment #investor #vc #molecular #drug #discovery #healthcare #market #business

[Adrian Rubstein @adrianrubstein]

Which is the state of the art for NASH? If you want to know more, take 5 and read the latest issue of #biobusiness

https://t.co/FGjf1j8olo

#biotech #investment #investor #vc #nash #obesity #diabetes #healthcare #market #business

[Adrian Rubstein @adrianrubstein]

Attention to all the Biotech community and investors 💡💡 The latest issue of #Biobusiness is out today

#biotech #investment #investor #vc #nash #obesity #diabetes #healthcare #market #Business

https://t.co/GCvLKUcfs6

[Adrian Rubstein @adrianrubstein]

From the people that brought you the #Biobusiness newsletter comes the Video Biobusiness newsletter, hope you enjoy it.

https://t.co/Cg1eiOAvwT

#biotech #investment #investor #vc #nash #obesity #diabetes #healthcare #market #business

[Adrian Rubstein @adrianrubstein]

Have you heard of CAR-T? They are not very good for solid tumors so, meet their little sister CAR-M:
https://t.co/p2q0l2ljEC

#science #biotech #cancer #investment #startups #VentureCapital

[Adrian Rubstein @adrianrubstein]

Unlocking the Undruggable Proteome with Targeted Protein Degradation, by @adrianrubstein https://t.co/dIFaFY5I0e

[Adrian Rubstein @adrianrubstein]

At this point in time, many of you have heard about gene editing and CRISPR with the objective of treating many diseases but, what happens when the gene is not the issue but its regulatory region? Who´s investing on it?

https://t.co/1xx1rvEtzk

#investment #Biotechnology

[Adrian Rubstein @adrianrubstein]

When AI meets Cell reprograming... want to learn more?

https://t.co/8oABfUSpyB

#Biotechnology #investment #ai

[Adrian Rubstein @adrianrubstein]

BioBusiness: Using Digital Twins To Improve Drug Development and Delivery https://t.co/GzC9jCNUHC

[Adrian Rubstein @adrianrubstein]

@twhitfill The only asset that is missing out is CNS. Would be great to have a partner column to foresee potential licensing agreements or M&A...??

[Adrian Rubstein @adrianrubstein]

Are you aware that only 1.9% of Venture Capital goes to FemTech?
FemTech is getting a lot of attention, so this new issue comes with a bonus. Do you want to learn more?

https://t.co/0E2btWamG9

#medicine #investment #investor #biotechnology
#startups #finance #femtech

[Adrian Rubstein @adrianrubstein]

BioBusiness -- Big Money in Biotech: Private Equity Firms Betting Big https://t.co/JjSST3Iktp

[Adrian Rubstein @adrianrubstein]

BioBusiness: Harnessing the Power of the Brain in Investing https://t.co/039qNsMxGK

[Adrian Rubstein @adrianrubstein]

The Game of Investment - Imagine a scenario where founders and investors are negotiating a deal. They can engage in a non-zero-sum game or in a zero-sum game.

Want to learn more?
👇👇👇

https://t.co/ialsgCXfit

#invest #startups #strategy #business

[Adrian Rubstein @adrianrubstein]

Uncertainty and Investing: Exploring the Ellsberg Paradox. Want to read more? 👇👇👇

https://t.co/Lf8HxJ1LlG

#Entrepreneurship #startups #invest

[Adrian Rubstein @adrianrubstein]

We are at the beginning of a Recession or recession? What does it mean for Biotechnology?...💎🙌💎🙌

https://t.co/W1g4BzMOjb

#investment #biotechnology #pharma #strategy #funding #markets
#investor #vc #privateequity #biotech #company #companies #startup #startups #development

[Adrian Rubstein @adrianrubstein]

Pre-clinical new platforms for drug development do not appear as trends for 2023, nevertheless, their potential impact is huge. Want to learn more?

https://t.co/gcQdb3Qqf9

#biotech #investment #finance #ai #future #healthcare

[Adrian Rubstein @adrianrubstein]

So, which is the preferred method of valuation? rNPV is primarily used by big pharma to value and structure deals involving drug development projects. Nevertheless, we need to take into account the probability of success, so ROV will be a more suitable model for this.

[Adrian Rubstein @adrianrubstein]

Biotech startup's valuations are going up and down but, are we calculating them correctly?

Which frame do use you as an investor?

#investor #biotech #investment #Financial

[Adrian Rubstein @adrianrubstein]

Real Option (ROV):

Real Options Analysis is a powerful tool that allows organizations to accurately assess the value of projects affected by economic uncertainty.

Investors can make informed decision take into account the project's potential upsides and downsides.